Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Raymond James: 'The topline numbers presented by Black Diamond today indicate that the company has a viable asset in our view'
May 22, 2026 9:38 AM EDTRaymond James analyst Sean McCutcheon reiterated an Outperform rating and $11.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).
The analyst comments "Thursday, after market close, ASCO 2026 regular abstracts were released, and in conjunction Black Diamond reported the topline result for the longer-term follow-up from their Phase 2... More
Stifel Defending Black Diamond Therapeutics (BDTX): 'we believe investors are underappreciating the breadth of mutation silevertinib is showing'
May 22, 2026 9:37 AM EDTStifel analyst Laura Prendergast reiterated a Buy rating and $8.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).
The analyst comments "We view the preliminary median PFS of 15.2 months as highly encouraging and perhaps practice changing - the DoR had not yet been reached. 44% of patients are progression free/still on drug with median follow up ~9.8 months, suggesting PFS could increase with longer follow up. What stands out to us the most is: The breadth of mutations seen in patients who are progression free for 1 year (10 unique mutations across 8 patients). The lack of any CNS... More
